NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-17-045 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HL-18-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites clinical research applications to investigate HIV-associated sleep disorders in adults or children using a variety of resources (e.g., existing cohorts, sample repositories) and methodologies (cellular/molecular/genomic approaches and/or vertebrate animal models). The purpose of this FOA is to elucidate mechanisms and mediators of sleep and circadian disturbances in people living with HIV, and the consequences and influences of these disturbances on other HIV-related heart, lung and blood comorbidities. Studies should address hypotheses mechanistically connecting sleep-associated disorders in the context of HIV with molecular/cellular pathways that may be related to prevalent HIV-related cardiopulmonary and/or hematological comorbidities. This FOA requires interdisciplinary collaborations among scientists across a range of relevant disciplines including circadian biology, sleep, and HIV.
Funding Opportunity PA-17-219 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption.
Funding Opportunity PA-17-220 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption.
Notice NOT-HD-17-006 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HL-18-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) announces a limited competition opportunity to support the Genomics and Informatics Center (GIC) for the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS). Only the institution that is currently the site of the SPIROMICS GIC is eligible to apply. The awardee will provide the overall coordination, data management, biorepository management, regulatory, statistical/analytical, and operational support for the program. The awardee will be responsible for oversight and maintenance of data and biospecimens collected under the SPIROMICS contracts, as well as coordination of ongoing and future SPIROMICS-related projects and ancillary studies. The awardee will also ensure that SPIROMICS participants continue to be contacted on a regular basis to enable retention and endpoints assessment.
Funding Opportunity PAR-17-217 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies including, but not limited to, those addressing health economics (e.g. tax and pricing policies, insurance coverage for tobacco dependence treatment). Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. This FOA provides funding for up to 2-years for research planning, intervention delivery, dissemination and implementation. Applicants submitting proposals related to health economics are encouraged to consult NOT-OD-16-025 to ensure that proposals align with NIH mission priorities in health economics research
Funding Opportunity PAR-17-218 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies including, but not limited to, those addressing health economics (e.g. tax and pricing policies, insurance coverage for tobacco dependence treatment). Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. This FOA provides funding for up to 2-years for research planning, intervention delivery, dissemination and implementation. Applicants submitting proposals related to health economics are encouraged to consult NOT-OD-16-025 to ensure that proposals align with NIH mission priorities in health economics research.
Funding Opportunity RFA-OD-17-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for a Center for Coordination of Analytics, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science. CASEL will support the scientific research programs funded by the Food and Drug Administration (FDA) Center for Tobacco Products (CTP), and will facilitate synthesis, coordination and communications of research and career enhancement within those programs. The overall objective of CASEL is to support research programs that can inform the FDA CTP in tobacco product regulatory activities and actions. Through leadership, coordination, and facilitation of collaborative efforts, CASEL can accelerate the advancement of science relevant to the Family Smoking Prevention and Tobacco Control Act (FSPTCA). The NIH and the FDA have formed an interagency partnership to foster research relevant to FDA's tobacco regulatory authorities. The award under this FOA will be administered by the NIH using designated funds from the FDA CTP for tobacco regulatory science mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.
Funding Opportunity RFA-OD-17-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for Tobacco Centers of Regulatory Science (TCORS) to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
Funding Opportunity RFA-CA-17-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites revision applications from currently funded NCI P50 Specialized Centers. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published in RFA-CA-17-017 and RFA-CA-17-018 that are intended for new R01 and R21 applications, respectively. This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to a new research project expanding the scope, yet integrated into the overall theme, of the entire parent P50 award.
Funding Opportunity RFA-CA-17-019 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI R01 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-17-017 (R01) and RFA-CA-17-018 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent R01 award.
Funding Opportunity RFA-CA-17-021 from the NIH Guide for Grants and Contracts. Projects. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published in RFA-CA-17-017 and RFA-CA-17-018 that are intended for new R01 and R21 applications, respectively. This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to a new research project expanding the scope, yet integrated into the overall theme, of the entire parent P01 award.
Funding Opportunity RFA-CA-17-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI U01 research project awards. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-17-017 (R01) and RFA-CA-17-018 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent U01 award.
Notice NOT-AI-17-015 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-17-008 from the NIH Guide for Grants and Contracts. The purpose of this Research Demonstration and Dissemination Projects (R18) Funding Opportunity Announcement (FOA) is to encourage research applications to test approaches to improve kidney disease prevention and/or treatment in routine healthcare settings. Research applications should be designed to test practical and potentially sustainable strategies that target the prevention or improved care of kidney disease, or the prevention or delay of the complications of kidney disease. The goal of the research is to obtain results that will improve routine healthcare practice and inform healthcare policy for the prevention or management of these conditions.
Funding Opportunity PAR-17-216 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for investigator-initiated clinical trials of natural products to treat clinical symptoms such as those associated with sleep disturbance, pain conditions, or some mental health conditions (e.g., mild to moderate depression, anxiety, and post-traumatic stress), or examine the effects of probiotics and other natural products on gut-microbiome interactions with the brain and/or immune system. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable biological signature (i.e., measure of the mechanism of action), whenever it is possible or practical to measure and used by the patient population of interest.
Funding Opportunity PAR-17-174 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for investigator-initiated multi-site clinical trials (Phase III and beyond) to study the effects of natural products in NCCIH designated areas of high research priority. Applicants should describe plans for a Clinical Coordinating Center to develop and implement the proposed multi-site clinical trial. The objective of the Clinical Coordinating Center is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The Clinical Coordinating Center is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism.
Funding Opportunity PAR-17-172 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-17-174. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH.
Funding Opportunity PAR-17-173 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-17-175. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH.